Drug Type Biosimilar, Monoclonal antibody |
Synonyms Adalimumab biosimilar, JY-026, JY026 |
Target |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plaque psoriasis | Phase 1 | CN | 30 Jan 2022 | |
Ankylosing Spondylitis | Phase 1 | CN | 05 Feb 2020 | |
Rheumatoid Arthritis | Phase 1 | CN | 05 Feb 2020 | |
Crohn Disease | IND Application | CN | 08 May 2015 | |
Juvenile Idiopathic Arthritis | IND Application | CN | 08 May 2015 |